ProBio Boosts CDMO Services with New Hopewell Facility

• ProBio Inc. opens a new facility in Hopewell, NJ, expanding plasmid DNA and viral vector manufacturing capabilities.

• The 128,000-square-foot facility will support North American operations for cell and gene therapies.

ProBio Inc., a New Jersey-based contract development and manufacturing organization (CDMO), has expanded its manufacturing capabilities with the opening of a new facility in Hopewell, New Jersey. This new site will serve as the hub for North American operations, significantly enhancing ProBio’s ability to support cell and gene therapy manufacturing.

The Hopewell facility spans approximately 128,000 square feet and includes office, laboratory, and manufacturing spaces. It is equipped with the latest technology for process development and current good manufacturing practice (cGMP) production of plasmid DNA and viral vectors, including adeno-associated virus, lentivirus, and retrovirus.

The site will support tech transfer, method and analytical development, process development, and drug substance and product manufacturing for both clinical and commercial-grade plasmid DNA and viral vector-based therapies. All operations will be maintained with rigorous quality control and quality assurance processes.

“We are proud to expand our capabilities to manufacture life-changing biologic drugs to the growing cell and gene therapy industry. Our dedicated, talented team and state-of-the-art manufacturing facility here in Hopewell, N.J., will help expedite bringing these therapies to patients,” said Li Chen, CEO of ProBio Inc.

Patrick Liu, Chairman of ProBio Inc., added, “The Hopewell facility exemplifies our mission to bring innovative therapies from concept to reality. By enhancing our capabilities, we not only support the rapid development of novel treatments but also ensure that these therapies reach patients more efficiently and effectively.”